Piper Sandler maintains argenx at Overweight, raises price target to $1350 from $1215

Piper Sandler raised its price target for argenx to $1350 from $1215, an 11.1% increase, implying 53.7% upside from the Nov 13 close. Recent analyst targets range from $1090 to $1336.

Original reporting
Published Nov 16, 2026, 1:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 1:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Piper Sandler maintains argenx at Overweight, raises price target to $1350 from $1215 — source image
Decision brief

The 30-second read

$ARGXBullishLow
01

Why it matters

The price target increase signals confidence in upcoming milestones, but the actual catalyst remains pending.

02

Market read

Analyst target upgrades can drive short-term price moves, especially in high‑volatility biotech stocks.

03

What to watch

Potential dilution from upcoming financing rounds not addressed.

Relevance 4/10Novelty 5/10Timing: today

Background

argenx is a clinical-stage biotech developing antibody therapies. Analyst coverage influences its valuation.

Company-level read

Ticker impact

$ARGXBullishMedium confidence
Context

Piper Sandler raised its price target on argenx to $1350 from $1215, indicating a fresh bullish analyst view.

Expected impact

potential upside pressure as the market prices in the higher target

Evidence & confidence

The new target suggests a 53.7% upside from the recent close, likely prompting short-term interest.

Market effects

May lift sentiment in the biotech sector as peers see similar analyst optimism.

Limited to US-listed biotech investors.

Low global impact beyond sector.

Counterpoint

The target raise could be premature if upcoming trial data disappoints.

Key entities

  • Piper Sandler

    Equity research firm that raised the price target.

  • argenx

    Biotech firm receiving the upgraded target.

Related articles

HighAI 9/10

Argenx: Up To $1.15 Billion Acquisition Of Unnatural Products To Expand Peptide Drug Discovery Platform

Argenx (ARGX) agreed to acquire Unnatural Products (UNP) for up to $1.15B, including $550M upfront. The deal expands Argenx's drug discovery platform to include macrocyclic peptides, potentially enabling oral and long-acting treatments. UNP's tech will complement Argenx's antibody engineering expertise. The transaction is expected to close by late 2026, subject to conditions.

$ARGXHighAI 9/10

Argenx Expands Immunology Capabilities with Up-to-$1.15B UNP Acquisition

Argenx (ARGX) agreed to acquire Unnatural Products (UNP) for up to $1.15B, combining UNP's peptide discovery platform with Argenx's immunology expertise. The deal includes $550M upfront and $595M in milestones. Argenx shares rose 5% on Euronext and 4% on Nasdaq following the announcement. Argenx's Vyvgart franchise reported $4.534B in net sales for 2026's first nine months, up 58% year-over-year.

HighAI 9/10

argenx to acquire biotech Unnatural Products for $1.15bn

argenx (ARGX) will acquire Unnatural Products (UNP) for up to $1.15bn, including $550m upfront. The deal adds macrocyclic peptide capabilities to argenx's immunology portfolio. UNP's team will continue operations in Santa Cruz, California, post-acquisition. The transaction is expected to close by year-end.

HighAI 9/10

Argenx Adds Oral Peptides to Its Immunology Strategy With $550M UNP Acquisition

Argenx acquires Unnatural Products (UNP) for $550M upfront, gaining oral peptide drug capabilities. UNP's macrocyclic peptides resist digestion, enabling oral administration. Argenx's Vyvgart had $4.5B sales in 2026, up 58.1%. The deal complements Argenx's antibody expertise and competes with big pharma in immunology. UNP could receive up to $595M in milestones.